Advertisement

What's Next for Eli Lilly's COVID-19 Antibodies?

What's Next for Eli Lilly's COVID-19 Antibodies?

The race to develop lifesaving COVID-19 treatments recently took a surprise turn for the worse. Eli Lilly's (NYSE: LLY) COVID-19 treatment candidate, an antibody called LY-CoV555, flopped in a clinical trial with hospitalized patients.